Salomon Banarer, MD
Endocrinology, Diabetes & Metabolism · Dallas, TXNPI 1841232444
Payments from drug & device makers
Across 347 payments — averaging $35.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$4K
- Novo Nordisk$2K
- Medtronic$1K
- AstraZeneca$1K
- Dexcom, Inc.$390
- Abbott$379
- plus $3K from 32 others
What the payments were for
- Consulting fees$1,87015%
- Speaking & faculty fees$3,80531%
- Travel & lodging$1,17610%
- Food & beverage$5,45944%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 16 | $3,750 |
| Novo Nordisk | 35 | $2,248 |
| Medtronic | 18 | $1,424 |
| AstraZeneca(2 entities) | 55 | $1,014 |
| Dexcom, Inc. | 32 | $390 |
| Abbott | 22 | $379 |
| Insulet Corporation | 18 | $270 |
| Amarin Pharma, Inc. | 16 | $256 |
| Xeris Pharmaceuticals, Inc. | 13 | $239 |
| Corcept Therapeutics | 10 | $237 |
| Boehringer Ingelheim | 11 | $223 |
| Sanofi-aventis U.S. LLC | 11 | $208 |
| Mannkind Corporation | 13 | $198 |
| Novartis | 8 | $159 |
| Amneal Pharmaceuticals LLC | 10 | $159 |
| Lilly USA, LLC | 8 | $118 |
| Ascensia Diabetes Care US Inc. | 4 | $110 |
| Sanofi | 1 | $105 |
| Merck | 7 | $99 |
| Amgen(2 entities) | 5 | $91 |
| BD | 5 | $91 |
| Sequel Med Tech, LLC | 3 | $79 |
| Zealand Pharma US, Inc. | 4 | $78 |
| Antares Pharma, Inc. | 4 | $50 |
| AbbVie | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Embecta Corp. | 2 | $37 |
| Recordati_rare_diseases_inc. | 1 | $35 |
| Johnson & Johnson | 2 | $29 |
| Cequr Corporation | 1 | $27 |
| Shire North American Group Inc | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| BETA Bionics, Inc. | 1 | $15 |
| Alvogen Inc | 1 | $14 |
| Nevro Corp. | 1 | $12 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$2,700
- Victoza$1,870
- Minimed 670G System$1,103
- t:slim X2 insulin pump$1,000
- SOLIQUA 100/33$105
How this compares
$12,310 in reported general payments places this provider in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 300 | $521,333 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $121,263 |
| MounjaroTirzepatide | 86 | $115,235 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $75,883 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 57 | $73,972 |
| JardianceEmpagliflozin | 54 | $68,996 |
| Xigduo XrDapaglifloz Propaned/Metformin | 58 | $62,911 |
| FarxigaDapagliflozin Propanediol | 62 | $59,940 |
| TrulicityDulaglutide | 30 | $43,109 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $31,738 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $30,979 |
| JanuviaSitagliptin Phosphate | 18 | $29,856 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $25,725 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $22,859 |
| Novolog FlexpenInsulin Aspart | 52 | $13,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,248 | $521,333300 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $118 | $161,470128 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $223 | $142,968111 claims |
| AstraZenecaFarxiga | $1,014 | $59,94062 claims |
| MerckJanuvia | $99 | $29,85618 claims |
| AbbVieSynthroid | $42 | $7,36682 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $159 | $3,033274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Dallas
- Julio RosenstockDallas$24.9M
- Ildiko LingvayDallas$8.2M
- Peter BresslerDallas$4.2M
- Steve FordanDallas$2.8M
- Pablo MoraDallas$2.1M
- Saleemah FahmiDallas$1.2M
- Priscilla HollanderDallas$1M
- Oksana HamidiDallas$1M
- Amy ShahDallas$953K
- Abhimanyu GargDallas$920K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.